1984
Prolonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trialsFactors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma. Blood 1981, 58: 45-51. DOI: 10.1182/blood.v58.1.45.45.Peer-Reviewed Original ResearchLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesPredicting Long-Term SurvivalExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosis
1979
Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy
Young R, Howser D, Anderson T, Fisher R, Jaffe E, DeVita V. Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy. The American Journal Of Medicine 1979, 66: 435-443. PMID: 433950, DOI: 10.1016/0002-9343(79)91065-9.Peer-Reviewed Original ResearchConceptsCentral nervous systemCNS diseaseHodgkin's lymphomaCentral nervous system complicationsNervous system complicationsWhole-brain irradiationGood clinical responseBone marrow involvementTime of diagnosisGroup of patientsAdvanced diseaseBrain irradiationClinical remissionCNS prophylaxisIntrathecal chemotherapyLymphomatous meningitisProphylactic therapyClinical responseMarrow involvementPositive cytologyMalignant lymphomaSystem complicationsLumbar punctureNodular lymphomaRisk factors
1976
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Bunn P, Schein P, Banks P, DeVita V. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976, 47: 3-10. PMID: 1106798, DOI: 10.1182/blood.v47.1.3.bloodjournal4713.Peer-Reviewed Original ResearchConceptsLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complicationsCentral Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited
Bunn P, Schein P, Banks P, DeVita V. Central Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited. Blood 1976, 47: 3-10. DOI: 10.1182/blood.v47.1.3.3.Peer-Reviewed Original ResearchLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complications
1975
American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations
Banks P, Arseneau J, Gralnick H, Canellos G, DeVita V, Berard C. American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations. The American Journal Of Medicine 1975, 58: 322-329. PMID: 163581, DOI: 10.1016/0002-9343(75)90598-7.Peer-Reviewed Original ResearchMeSH KeywordsAbdomenAdolescentAdultAutopsyBiopsyBone MarrowBurkitt LymphomaChildChild, PreschoolCytoplasmFemaleHumansInclusion BodiesIntestinal NeoplasmsIntestine, SmallLiverLymphatic MetastasisMacrophagesMaleMandibular NeoplasmsMaxillary NeoplasmsNorth AmericaOvarian NeoplasmsSouth AmericaUnited StatesConceptsMonths of therapyBone marrow involvementOlder median ageCentral nervous systemInitial therapyClinicopathologic studyMarrow involvementBurkitt's typeMedian ageMultiorgan involvementMalignant lymphomaShorter survivalMassive infiltrationAmerican patientsPelvic sitesPathologic correlationDiffuse necrosisHistologic appearanceTherapeutic implicationsOrgan sitesBone marrowNervous systemEndemic regionsTumor cellsLymphoma
1974
Cyclical Combination Chemotherapy for Advanced Breast Carcinoma
Canellos G, Devita V, Gold G, Chabner B, Schein P, Young R. Cyclical Combination Chemotherapy for Advanced Breast Carcinoma. The BMJ 1974, 1: 218. PMID: 4818162, PMCID: PMC1633086, DOI: 10.1136/bmj.1.5901.218.Peer-Reviewed Original ResearchConceptsMedian survivalMetastatic lesionsAdvanced metastatic breast cancerCyclical combination chemotherapyOverall median durationAdvanced breast carcinomaBone marrow involvementMetastatic breast cancerMetastasis-free intervalSoft tissueExtensive radiotherapyPrevious chemotherapyComplete remissionHaematological toxicityHormonal therapyLiver dysfunctionMarrow involvementMedian durationCombination chemotherapyEndocrine ablationBreast carcinomaBreast cancerPatientsMonthly cyclesChemotherapy